CompletedNCT02970305
Pimavanserin for Negative Symptoms of Schizophrenia: A Placebo-Controlled Trial
About this title
Read the official source — NCT02970305This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
Medication studyAges 18–55Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Phoenix and 100 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: November 4, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 403
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada, Bulgaria, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02970305
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix, United States · Rogers, United States · Bellflower, United States
79 more locations
- Lemon Grove, United States
- Norwalk, United States
- San Diego, United States
- Santa Ana, United States
- Torrance, United States
- Hialeah, United States
- Lauderhill, United States
- Miami, United States
- Tampa, United States
- Atlanta, United States
- Decatur, United States
- Marietta, United States
- Chicago, United States
- Hoffman Estates, United States
- Wichita, United States
- Ann Arbor, United States
- Las Vegas, United States
- Berlin, United States
- Albuquerque, United States
- Rochester, United States
- Charlotte, United States
- Durham, United States
- Oklahoma City, United States
- Downingtown, United States
- Charleston, United States
- Irving, United States
- Richardson, United States
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Tserova Koria, Bulgaria
- Varna, Bulgaria
- Penticton, Canada
- Chatham, Canada
- Montreal, Canada
- Toronto, Canada
- Hradec Králové, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Říčany, Czechia
- Kalocsa, Hungary
- Budapest, Hungary
- Debrecen, Hungary
- Gyula, Hungary
- Pécs, Hungary
- Bialystok, Poland
- Bydgoszcz, Poland
- Lublin, Poland
- Pruszcz Gdański, Poland
- Roshchino, Russia
- Plekhanovo, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Smolensk, Russia
- Stavropol, Russia
- Yaroslavl, Russia
- Yekaterinburg, Russia
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Valladolid, Spain
- Zamora, Spain
- Dnipro, Ukraine
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Oleksandrivka, Ukraine
- Poltava, Ukraine
- Smila, Ukraine
- Vinnytsia, Ukraine
- Czechia
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Pimavanserin for people with schizophrenia.
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including Pimavanserin and Placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
